Key Highlights

  • Clinuvel filed a marketing authorisation dossier for NEURACTHEL Instant through the European decentralised procedure.
  • NEURACTHEL Instant is a branded generic formulation of tetracosactide, a synthetic analogue of ACTH.
  • Three EU Member States have been identified as initial launch markets.
  • The decentralised procedure requires 300 days of review plus clock stops.

CLINUVEL PHARMACEUTICALS LTD (ASX:CUV) announced on 30 October 2026 that it has filed a dossier for marketing authorisation of its second pharmaceutical product, NEURACTHEL Instant. The filing was made with national European regulators through the decentralised procedure. The product is a branded generic formulation of tetracosactide, a synthetic peptide analogue of the naturally occurring hormone ACTH.

The Regulatory Filing

If the product is approved, Clinuvel will be able to sell NEURACTHEL Instant as a prescription medicine in up to three initial European Union Member States. The company has chosen those markets on the basis of its commercial priorities.

The decentralised procedure involves national regulators in several countries reviewing the same dossier at the same time. The company says the review requires 300 days plus clock stops, which are periods in which the company responds to regulator questions.

The decentralised procedure requires one reference regulator to coordinate the review across the countries involved, with each national authority then reaching its own decision. The company's announcement sets out the review period it expects, but the outcome of each national assessment will be determined by the regulators themselves.

Background on ACTH Products

ACTH is a 39-amino acid peptide hormone in the melanocortin family. The company notes that naturally occurring and synthetic ACTH products are approved as systemic therapy in the United States for 19 conditions, including infantile spasms and acute exacerbations of multiple sclerosis.

In Europe, ACTH products are used both as therapy and as a diagnostic tool for adrenal insufficiency. Tetracosactide, the active ingredient in NEURACTHEL Instant, is a 24-amino acid analogue of the natural hormone.

Implications for the Company's Pipeline

NEURACTHEL Instant is the second pharmaceutical product that Clinuvel has taken into regulatory review. The filing extends the company's product portfolio beyond its existing offering.

Approval is not yet assured, and the announcement does not provide a timetable for a decision beyond the review period it describes.

Final Word

Clinuvel's filing of NEURACTHEL Instant starts the European review of a second pharmaceutical product, with an assessment period of at least 300 days. The company has named three initial markets for launch if the product is approved. Future announcements will indicate the progress of the review through the regulators involved.